Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiora Pharmaceuticals (KPRX) EPS (Basic) (2016 - 2025)

Kiora Pharmaceuticals' EPS (Basic) history spans 11 years, with the latest figure at -$1.56 for Q4 2025.

  • For Q4 2025, EPS (Basic) fell 35.65% year-over-year to -$1.56; the TTM value through Dec 2025 reached -$2.61, down 219.72%, while the annual FY2025 figure was -$2.6, 379.57% down from the prior year.
  • EPS (Basic) reached -$1.56 in Q4 2025 per KPRX's latest filing, down from $0.01 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $4.67 in Q1 2024 to a low of -$21.43 in Q4 2021.
  • Average EPS (Basic) over 5 years is -$3.57, with a median of -$0.9 recorded in 2023.
  • Peak YoY movement for EPS (Basic): crashed 8829.17% in 2021, then skyrocketed 567.0% in 2024.
  • A 5-year view of EPS (Basic) shows it stood at -$21.43 in 2021, then skyrocketed by 71.86% to -$6.03 in 2022, then soared by 85.07% to -$0.9 in 2023, then decreased by 27.78% to -$1.15 in 2024, then crashed by 35.65% to -$1.56 in 2025.
  • Per Business Quant, the three most recent readings for KPRX's EPS (Basic) are -$1.56 (Q4 2025), $0.01 (Q3 2025), and -$0.54 (Q2 2025).